Drug Profile
ULAH 99
Latest Information Update: 16 Oct 2003
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antiarrhythmics
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 02 Apr 2003 Discontinued - Preclinical for Arrhythmias in Germany (unspecified route)
- 02 Apr 1997 No-Development-Reported for Arrhythmias in Germany (Unknown route)
- 24 Oct 1994 Preclinical development for Arrhythmias in Germany (Unknown route)